Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world first-line camrelizumab for advanced metastatic colorectal cancer
ChiCTR2100051459Phase 4Not yet recruiting
- Sponsor
- Quanzhou First Hospital
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in metastatic colon cancer (mCRC), sponsored by Quanzhou First Hospital. Primary endpoint: Objective response rate. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on ChiCTR2100051459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051459.